For the quarter ending 2026-03-31, PLX had $26,321K increase in cash & cash equivalents over the period. $21,264K in free cash flow.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net income (loss) | 18,317 | -5,504 | 2,355 | -3,455 |
| Share-based compensation | 532 | 732 | 598 | 967 |
| Depreciation | 404 | 387 | 372 | 706 |
| Financial (income) expenses, net | -158 | -470 | -28 | -108 |
| Changes in accrued liability for employee rights upon retirement | 5 | 8 | 4 | 10 |
| Changes in deferred income tax asset | 71 | 163 | 59 | 118 |
| Gain on amounts funded in respect of employee rights upon retirement | - | 2 | 12 | 6 |
| Loss (gain) on sale of fixed assets | - | 0 | - | - |
| Gain on conversions of convertible notes | - | 0 | - | - |
| Amortization of debt issuance costs and debt discount | - | 0 | - | - |
| Decrease in contracts liability | - | 0 | - | - |
| Decrease (increase) in accounts receivable-trade and other assets | -6,408 | -5,878 | 4,849 | 6,919 |
| Changes in operating lease right of use assets, net | -55 | -47 | 24 | 38 |
| Decrease (increase) in inventories | 4,745 | 4,474 | 124 | -112 |
| Increase (decrease) in accounts payable and accruals | 820 | 4,325 | -2,139 | -1,894 |
| Net cash provided by (used in) operating activities | 22,025 | 2,030 | -3,732 | -10,291 |
| Investment in bank deposits | 5,000 | 5,000 | - | - |
| Short-term deposit withdrawal | 10,000 | 5,000 | - | - |
| Purchase of property and equipment | 761 | 403 | 498 | 737 |
| Proceeds from sale of property and equipment | - | 0 | - | - |
| Amounts funded in respect of employee rights upon retirement, net | 7 | 7 | 6 | 13 |
| Increase in restricted deposit | 9 | 702 | - | - |
| Net cash provided by (used in) investing activities | 4,223 | -1,112 | -504 | -750 |
| Payment for convertible notes redemption | - | 0 | - | - |
| Proceeds from issuance of common stock under the sales agreement, net | - | 0 | 0 | 6,812 |
| Exercise of warrants and options | 150 | 146 | 0 | 2,368 |
| Net cash provided by financing activities | 150 | 146 | 0 | 9,180 |
| Effect of exchange rate changes on cash and cash equivalents | -77 | -31 | -12 | -4 |
| Net increase (decrease) in cash and cash equivalents | 26,321 | 1,033 | -4,248 | -1,865 |
| Balance of cash and cash equivalents at beginning of period | 14,680 | 13,647 | 19,760 | - |
| Balance of cash and cash equivalents at end of period | 41,001 | 14,680 | 13,647 | - |
Protalix BioTherapeutics, Inc. (PLX)
Protalix BioTherapeutics, Inc. (PLX)